Announced that individual enrollment has begun in a Stage 2a today.

Alvine Pharmaceuticals commences Stage 2a medical trial to evaluate the efficacy of ALV003 Alvine Pharmaceuticals, Inc. Announced that individual enrollment has begun in a Stage 2a today, randomized, double-blind, placebo-controlled study to measure the efficacy and safety of ALV003 for use in the treating celiac disease. Adelman, M http://himcolin.org/ more info .D. Related StoriesOne nights sleep deficiency and six months on high-fat diet plan could both impair insulin sensitivityConsuming high-fat diet can lead to anxiousness and depression, trigger measurable adjustments in the brainDiet missing soluble fiber promotes swelling in the intestines, leading to weight gainThe objective of the study is to assess the potential for patient benefit and collect safety data regarding repeat dosing with ALV003, as well as to assess potential endpoints for use in subsequent Phase 2b and 3 studies.